MeSH term
Frequency | Condition_Probility | Humans | 405 | 0.0 |
Adolescent | 18 | 0.0 |
Child, Preschool | 25 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
Male | 109 | 0.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Oxidation-Reduction | 9 | 0.0 |
*Point Mutation | 14 | 1.0 |
Research Support, Non-U.S. Gov't | 267 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 24 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 110 | 0.0 |
Adult | 54 | 0.0 |
Comparative Study | 42 | 0.0 |
Female | 119 | 0.0 |
Infusions, Intravenous | 2 | 0.0 |
Middle Aged | 29 | 0.0 |
Child | 34 | 0.0 |
Genotype | 73 | 0.0 |
Phenylalanine Hydroxylase/*genetics | 132 | 97.0 |
Phenylketonurias/*enzymology/genetics | 6 | 85.0 |
Biotransformation | 6 | 1.0 |
Carcinogens/*toxicity | 5 | 4.0 |
*Gene Expression Regulation, Enzymologic | 5 | 1.0 |
Isoenzymes/genetics | 4 | 1.0 |
Kinetics | 21 | 0.0 |
Polycyclic Hydrocarbons, Aromatic/*pharmacokinetics | 3 | 100.0 |
Structure-Activity Relationship | 8 | 0.0 |
Transcription, Genetic | 8 | 0.0 |
Tumor Cells, Cultured | 16 | 0.0 |
Aged | 14 | 0.0 |
Case-Control Studies | 6 | 0.0 |
DNA Adducts/*metabolism | 2 | 4.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Glutathione Transferase/genetics | 4 | 1.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Liver/*metabolism | 3 | 0.0 |
Polycyclic Hydrocarbons, Aromatic/*metabolism | 4 | 22.0 |
Polymerase Chain Reaction | 52 | 0.0 |
Polymorphism, Restriction Fragment Length | 48 | 2.0 |
Risk Factors | 5 | 0.0 |
Air Pollution, Indoor/*analysis | 2 | 50.0 |
Dust | 2 | 6.0 |
Environmental Monitoring | 3 | 7.0 |
Industry | 6 | 18.0 |
Mass Fragmentography | 3 | 1.0 |
*Occupational Exposure | 9 | 6.0 |
Polycyclic Hydrocarbons, Aromatic/*analysis | 12 | 92.0 |
Volatilization | 2 | 28.0 |
Benzo(a)pyrene/metabolism | 2 | 11.0 |
Carcinogens/*metabolism | 2 | 2.0 |
Pyrenes/*metabolism | 2 | 14.0 |
Cotinine/urine | 2 | 28.0 |
Cytochrome P-450 CYP1A1/genetics | 2 | 2.0 |
DNA Adducts | 2 | 2.0 |
*DNA Damage | 6 | 1.0 |
Exons | 28 | 0.0 |
Lymphocytes/drug effects | 2 | 2.0 |
*Mutagens | 2 | 6.0 |
*Polymorphism, Genetic | 23 | 0.0 |
Smoking | 4 | 1.0 |
China | 10 | 2.0 |
*Environmental Exposure | 3 | 4.0 |
*Environmental Monitoring | 3 | 9.0 |
*Food Contamination | 2 | 10.0 |
Public Health | 3 | 17.0 |
Soil Pollutants/*analysis | 3 | 60.0 |
Animals | 94 | 0.0 |
Base Sequence | 79 | 0.0 |
Molecular Sequence Data | 79 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Sequence Analysis, DNA | 7 | 0.0 |
Binding Sites/genetics | 3 | 0.0 |
Biopterin/*analogs & derivatives/*chemistry/metabolism | 2 | 100.0 |
Models, Molecular | 12 | 0.0 |
Mutagenesis, Site-Directed | 9 | 0.0 |
Protein Conformation | 16 | 0.0 |
Protons | 2 | 2.0 |
Recombinant Proteins/chemistry/metabolism | 3 | 0.0 |
Thermodynamics | 3 | 0.0 |
Tryptophan/genetics | 2 | 4.0 |
Alleles | 63 | 0.0 |
Asian Continental Ancestry Group | 6 | 2.0 |
English Abstract | 27 | 0.0 |
European Continental Ancestry Group | 5 | 0.0 |
Gene Frequency | 28 | 0.0 |
Pedigree | 36 | 0.0 |
Phenylketonurias/*diagnosis/genetics | 9 | 100.0 |
*Prenatal Diagnosis | 5 | 1.0 |
Blotting, Northern | 4 | 0.0 |
COS Cells | 7 | 0.0 |
DNA/chemistry/genetics | 4 | 0.0 |
DNA Mutational Analysis | 42 | 0.0 |
Gene Expression Regulation, Enzymologic | 7 | 0.0 |
Haplotypes | 53 | 2.0 |
Mutation | 51 | 0.0 |
Phenotype | 62 | 0.0 |
Phenylalanine Hydroxylase/deficiency/*genetics/metabolism | 5 | 100.0 |
Phenylketonurias/enzymology/genetics | 4 | 100.0 |
Polymorphism, Genetic | 16 | 0.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Sicily | 2 | 10.0 |
*Genetics, Population | 4 | 1.0 |
Linkage Disequilibrium | 4 | 0.0 |
Models, Genetic | 2 | 0.0 |
Quebec/epidemiology | 3 | 10.0 |
Infant | 21 | 0.0 |
Infant, Newborn | 39 | 0.0 |
*Mutation | 70 | 1.0 |
Phenylalanine Hydroxylase/genetics | 25 | 89.0 |
Phenylketonurias/diagnosis/*genetics | 6 | 100.0 |
Poland | 5 | 3.0 |
Conserved Sequence/genetics | 3 | 1.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Mice | 31 | 0.0 |
*Nuclear Proteins | 3 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Protein Binding | 9 | 0.0 |
Rats | 31 | 0.0 |
Regulatory Sequences, Nucleic Acid/*genetics | 2 | 2.0 |
Sequence Deletion | 8 | 0.0 |
Variation (Genetics) | 8 | 0.0 |
Asian Continental Ancestry Group/genetics | 5 | 1.0 |
European Continental Ancestry Group/genetics | 5 | 0.0 |
Gene Frequency/genetics | 2 | 0.0 |
Genetic Screening/*methods | 2 | 1.0 |
Heterozygote Detection/*methods | 2 | 3.0 |
Mutation/genetics | 9 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Time Factors | 10 | 0.0 |
Cloning, Molecular | 10 | 0.0 |
Cytochrome P-450 CYP1A1/metabolism | 3 | 4.0 |
Epoxide Hydrolases/metabolism | 2 | 12.0 |
Escherichia coli | 4 | 0.0 |
Models, Chemical | 2 | 0.0 |
Recombinant Proteins/metabolism | 7 | 0.0 |
Substrate Specificity | 6 | 0.0 |
Dihydropteridine Reductase/metabolism | 2 | 66.0 |
Netherlands | 3 | 1.0 |
Phenylalanine Hydroxylase/*deficiency/genetics | 6 | 100.0 |
Polymorphism, Single-Stranded Conformational | 9 | 0.0 |
Phenylketonurias/*diagnosis | 3 | 100.0 |
Pregnancy | 15 | 0.0 |
Prenatal Diagnosis/*methods | 3 | 2.0 |
Restriction Mapping | 9 | 0.0 |
Prevalence | 3 | 0.0 |
Soil/analysis | 2 | 25.0 |
Breath Tests/*methods | 2 | 28.0 |
Carbon Isotopes/diagnostic use | 2 | 18.0 |
Phenylalanine/blood | 20 | 71.0 |
Phenylalanine Hydroxylase/genetics/*metabolism | 2 | 100.0 |
Amino Acid Sequence | 28 | 0.0 |
Catalytic Domain | 6 | 2.0 |
Enzyme Activation | 4 | 0.0 |
Enzyme Stability | 3 | 1.0 |
Molecular Structure | 8 | 1.0 |
Phosphorylation | 4 | 0.0 |
Recombinant Proteins/isolation & purification | 2 | 4.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Chromatography, High Pressure Liquid | 11 | 0.0 |
Escherichia coli/metabolism | 3 | 1.0 |
Family Health | 6 | 0.0 |
Mutation, Missense | 7 | 0.0 |
Phenylalanine/metabolism | 7 | 21.0 |
Phenylketonurias/diagnosis/genetics | 5 | 100.0 |
Dimerization | 3 | 0.0 |
Heterozygote | 15 | 0.0 |
Hydro-Lyases/genetics | 2 | 33.0 |
Plasmids/metabolism | 2 | 0.0 |
Protein Biosynthesis | 6 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Antigens, Neoplasm/*genetics | 2 | 3.0 |
Chromosomes, Human, Pair 12/*genetics | 3 | 2.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Gene Deletion | 4 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Phenylalanine Hydroxylase/deficiency/*genetics | 20 | 100.0 |
Phenylketonurias/enzymology/*genetics/physiopathology | 2 | 100.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Catalysis | 7 | 0.0 |
Liver/*enzymology | 4 | 0.0 |
Phenylalanine Hydroxylase/*chemistry/metabolism | 3 | 100.0 |
Phenylalanine/*metabolism | 10 | 45.0 |
Cytochrome P-450 CYP1A1/*biosynthesis | 2 | 8.0 |
DNA Primers | 7 | 0.0 |
Enzyme Induction | 7 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Cell Division | 2 | 0.0 |
Phenylalanine/chemistry/metabolism | 2 | 66.0 |
Ultraviolet Rays | 2 | 0.0 |
Phenylketonurias/enzymology/epidemiology/*genetics | 3 | 100.0 |
Phenylketonurias/enzymology/*genetics | 22 | 95.0 |
*Mutation, Missense | 4 | 0.0 |
Phenylketonurias/*genetics | 64 | 98.0 |
Amino Acid Substitution | 10 | 0.0 |
Mutagenicity Tests | 2 | 1.0 |
Polycyclic Hydrocarbons, Aromatic/chemistry/*toxicity | 2 | 66.0 |
Urban Health | 3 | 7.0 |
Binding Sites | 7 | 0.0 |
Mutation, Missense/*genetics | 3 | 1.0 |
Phenylalanine Hydroxylase/*chemistry/genetics/*metabolism | 2 | 100.0 |
Cell Line | 15 | 0.0 |
Escherichia coli/genetics | 4 | 0.0 |
In Vitro | 12 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Stereoisomerism | 5 | 1.0 |
Dopamine/*metabolism | 2 | 1.0 |
Electron Spin Resonance Spectroscopy | 2 | 0.0 |
Ligands | 2 | 0.0 |
Biological Transport/drug effects | 3 | 1.0 |
Carcinoma, Renal Cell/*metabolism | 3 | 13.0 |
Dexamethasone/*pharmacology | 3 | 1.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
Kidney Neoplasms/*metabolism | 3 | 10.0 |
Triiodothyronine/*pharmacology | 2 | 4.0 |
p-Aminohippuric Acid/*pharmacokinetics | 2 | 100.0 |
RNA, Messenger/genetics | 6 | 0.0 |
Transfection | 9 | 0.0 |
Polycyclic Compounds/*analysis | 7 | 100.0 |
Smoke/*analysis | 2 | 50.0 |
Air Pollutants, Environmental/*analysis | 7 | 77.0 |
Environmental Exposure | 7 | 4.0 |
Environmental Monitoring/methods | 2 | 15.0 |
Placenta/*chemistry | 2 | 5.0 |
Biological Markers | 9 | 0.0 |
Sensitivity and Specificity | 5 | 0.0 |
Introns | 9 | 0.0 |
Polycyclic Hydrocarbons, Aromatic/*adverse effects | 2 | 18.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
Japan | 9 | 0.0 |
Neonatal Screening | 9 | 29.0 |
Biopterin/*analogs & derivatives/metabolism | 2 | 40.0 |
Gene Expression | 5 | 0.0 |
Gene Therapy/*methods | 3 | 0.0 |
Genetic Vectors | 6 | 0.0 |
Liver/enzymology | 14 | 2.0 |
Retroviridae/genetics | 2 | 0.0 |
Transfection/methods | 2 | 1.0 |
Enzyme Induction/drug effects | 2 | 0.0 |
Polycyclic Hydrocarbons, Aromatic/pharmacokinetics/*toxicity | 2 | 100.0 |
Cell-Free System | 2 | 0.0 |
Denmark | 6 | 3.0 |
Electrophoresis, Polyacrylamide Gel | 6 | 0.0 |
Phenylalanine Hydroxylase/chemistry/*genetics | 2 | 100.0 |
Phenylketonurias/genetics | 14 | 93.0 |
Rabbits | 3 | 0.0 |
Chromatography, Thin Layer | 2 | 1.0 |
DNA Adducts/*analysis | 6 | 13.0 |
Phosphorus Radioisotopes | 2 | 3.0 |
*Population Surveillance | 2 | 5.0 |
*DNA Mutational Analysis | 4 | 2.0 |
Brazil/epidemiology | 2 | 2.0 |
Mutation/*genetics | 12 | 0.0 |
Administration, Inhalation | 4 | 2.0 |
Chile | 3 | 5.0 |
Mutagens/*analysis | 2 | 11.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Polycyclic Hydrocarbons, Aromatic/*analysis/toxicity | 3 | 75.0 |
Seasons | 8 | 5.0 |
*Haplotypes | 13 | 5.0 |
Tandem Repeat Sequences | 2 | 1.0 |
Phenylalanine Hydroxylase/deficiency/genetics | 6 | 100.0 |
Models, Theoretical | 2 | 1.0 |
Cytochrome P-450 CYP1A1/*biosynthesis/genetics | 2 | 8.0 |
France | 2 | 0.0 |
Metabolic Detoxication, Drug | 2 | 2.0 |
Ethnic Groups/genetics | 4 | 2.0 |
*Minisatellite Repeats | 4 | 5.0 |
Russia | 4 | 4.0 |
Crystallography, X-Ray | 3 | 0.0 |
Frameshift Mutation | 2 | 0.0 |
Phenylketonurias/*enzymology/*genetics | 10 | 100.0 |
Sequence Deletion/genetics | 2 | 1.0 |
Italy | 9 | 1.0 |
Norway | 3 | 2.0 |
Protein Structure, Secondary | 3 | 0.0 |
Reference Values | 2 | 0.0 |
Sweden | 4 | 1.0 |
*Exons | 5 | 1.0 |
Phenylketonurias/enzymology/ethnology/*genetics | 4 | 100.0 |
Exons/genetics | 6 | 0.0 |
Far East | 2 | 22.0 |
Haplotypes/*genetics | 4 | 2.0 |
Phylogeny | 2 | 0.0 |
Polymorphism, Single Nucleotide/genetics | 2 | 0.0 |
Phenylalanine Hydroxylase/*genetics/isolation & purification/metabolism | 2 | 100.0 |
*Alleles | 7 | 0.0 |
Blotting, Western | 4 | 0.0 |
*Disease Models, Animal | 2 | 0.0 |
Phenylalanine Hydroxylase/*genetics/metabolism | 9 | 100.0 |
Biological Transport | 2 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
*Genetic Screening | 3 | 1.0 |
*Heterozygote Detection | 2 | 1.0 |
Phenylketonurias/*diagnosis/*genetics | 2 | 100.0 |
Point Mutation | 6 | 0.0 |
Phenylalanine/*blood | 13 | 61.0 |
Phenylketonurias/blood/*genetics | 2 | 100.0 |
Phenylalanine Hydroxylase/*metabolism | 5 | 83.0 |
Genetic Heterogeneity | 10 | 3.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Linkage (Genetics) | 12 | 0.0 |
Air Pollutants, Environmental/*analysis/toxicity | 2 | 100.0 |
Carcinogens/toxicity | 6 | 11.0 |
Cities | 4 | 50.0 |
Greece | 4 | 4.0 |
Inhalation Exposure | 2 | 9.0 |
Particle Size | 6 | 2.0 |
Risk Assessment | 8 | 0.0 |
Temperature | 2 | 0.0 |
*Urban Health | 3 | 37.0 |
Alcohol Drinking/adverse effects | 2 | 4.0 |
Breast/*metabolism | 2 | 3.0 |
Breast Neoplasms/etiology/genetics/*metabolism | 2 | 100.0 |
DNA Adducts/genetics/*metabolism | 2 | 40.0 |
DNA, Neoplasm/genetics/*metabolism | 2 | 16.0 |
Genetic Markers | 16 | 0.0 |
Guanine/analogs & derivatives/metabolism | 2 | 13.0 |
Lipid Peroxidation | 2 | 1.0 |
Oxidative Stress/genetics | 2 | 8.0 |
Smoking/adverse effects | 3 | 1.0 |
Chromatography, High Pressure Liquid/methods | 2 | 1.0 |
Kidney Cortex/*drug effects/metabolism | 2 | 100.0 |
Rats, Wistar | 4 | 0.0 |
Homozygote | 9 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Tissue Distribution | 5 | 0.0 |
Phenylalanine Hydroxylase/*deficiency | 4 | 100.0 |
Mice, Knockout | 3 | 0.0 |
Phenylketonurias/*enzymology | 2 | 100.0 |
*Genome | 3 | 2.0 |
Pteridines/*metabolism | 2 | 33.0 |
Air Pollutants/analysis | 2 | 66.0 |
Analysis of Variance | 3 | 0.0 |
Environmental Monitoring/*methods | 3 | 13.0 |
Intelligence/*genetics | 2 | 13.0 |
Minisatellite Repeats | 4 | 3.0 |
Gene Transfer Techniques | 3 | 0.0 |
Mice, Mutant Strains | 3 | 0.0 |
Egypt | 2 | 4.0 |
Polycyclic Hydrocarbons, Aromatic/*toxicity | 5 | 35.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Aerosols | 2 | 2.0 |
Mexico | 2 | 2.0 |
Vehicle Emissions/*analysis | 3 | 60.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
*Oxidoreductases | 2 | 2.0 |
*Oxidoreductases Acting on CH-CH Group Donors | 2 | 2.0 |
Chromosome Mapping | 12 | 0.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Kidney/*metabolism | 2 | 1.0 |
Fluorometry | 2 | 2.0 |
Cell Communication/*drug effects | 2 | 10.0 |
Cells, Cultured | 8 | 0.0 |
Cytochrome P-450 CYP1A1/genetics/metabolism | 2 | 6.0 |
Gap Junctions/*drug effects | 2 | 50.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Smoking/*adverse effects | 3 | 1.0 |
Polymorphism, Genetic/genetics | 4 | 0.0 |
Regression Analysis | 3 | 0.0 |
Air Pollutants, Occupational/*analysis | 4 | 28.0 |
Occupational Exposure/*analysis | 3 | 11.0 |
Romania | 2 | 11.0 |
*Coke | 2 | 33.0 |
Pyrenes/metabolism | 3 | 30.0 |
*Variation (Genetics) | 5 | 0.0 |
*Gene Amplification | 3 | 0.0 |
Prognosis | 3 | 0.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
Recombinant Fusion Proteins/genetics | 2 | 1.0 |
*Polymorphism, Restriction Fragment Length | 26 | 3.0 |
Amino Acid Metabolism, Inborn Errors/genetics | 2 | 25.0 |
Chromosomes, Human, Pair 12/genetics | 3 | 3.0 |
Blotting, Southern | 14 | 0.0 |
Lymphocytes | 2 | 1.0 |
*Polymerase Chain Reaction | 2 | 0.0 |
*Heterozygote | 3 | 0.0 |
Phenylketonurias/genetics/*metabolism | 4 | 100.0 |
Tyrosine/blood | 3 | 16.0 |
Chromosome Mapping/*methods | 2 | 1.0 |
*Evolution | 4 | 2.0 |
Species Specificity | 3 | 0.0 |
Europe | 10 | 3.0 |
Phenylketonurias/epidemiology/genetics | 2 | 100.0 |
Biological Transport, Active/drug effects | 2 | 3.0 |
Carcinoma, Hepatocellular | 3 | 0.0 |
Biological Availability | 2 | 0.0 |
*Carcinogens | 2 | 6.0 |
Genetics, Population | 8 | 2.0 |
Portugal | 2 | 3.0 |
Molecular Weight | 3 | 0.0 |
Carcinogens/chemistry/*toxicity | 2 | 100.0 |
CHO Cells | 2 | 0.0 |
Hamsters | 4 | 0.0 |
Carcinoma, Hepatocellular/metabolism | 2 | 2.0 |
DNA/analysis | 6 | 0.0 |
*Gene Expression | 2 | 0.0 |
Liver Neoplasms/metabolism | 2 | 2.0 |
Retroviridae/*genetics | 3 | 2.0 |
Phenylalanine Hydroxylase/biosynthesis/*genetics | 2 | 100.0 |
RNA Splicing | 3 | 0.0 |
Czech Republic | 3 | 6.0 |
Spain | 2 | 0.0 |
Phenylalanine/*blood/genetics/metabolism | 2 | 100.0 |
Benzo(a)pyrene/analysis | 2 | 50.0 |
Cohort Studies | 2 | 0.0 |
Phenylketonurias/epidemiology/*genetics | 4 | 100.0 |
Phenylketonurias/ethnology/*genetics | 5 | 100.0 |
Reproducibility of Results | 2 | 0.0 |
Air Pollutants/*analysis | 2 | 18.0 |
Polycyclic Compounds/analysis | 3 | 100.0 |
Spectrophotometry, Ultraviolet | 2 | 1.0 |
Quebec | 3 | 5.0 |
Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Incidence | 2 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Occupational Exposure/analysis | 2 | 40.0 |
Gene Expression Regulation | 4 | 0.0 |
DNA Primers/genetics | 3 | 0.0 |
Plasmids/genetics | 2 | 0.0 |
Fetal Diseases/*diagnosis/genetics | 2 | 22.0 |
Adenoviridae/genetics/immunology | 2 | 33.0 |
*Gene Therapy | 2 | 0.0 |
Amino Acid Metabolism, Inborn Errors/enzymology/*genetics | 4 | 22.0 |
Codon/genetics | 8 | 2.0 |
Phenylalanine Hydroxylase/*deficiency/genetics/metabolism | 2 | 100.0 |
Biopterin/analogs & derivatives/deficiency/genetics | 2 | 100.0 |
Genetic Screening | 9 | 1.0 |
Sequence Analysis | 4 | 1.0 |
United States | 2 | 0.0 |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide/analysis | 2 | 50.0 |
Cattle | 5 | 0.0 |
Iron | 2 | 20.0 |
Cross Reactions | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Polycyclic Compounds/*metabolism | 2 | 15.0 |
Mice, Inbred Strains | 3 | 0.0 |
Genetic Counseling | 2 | 1.0 |
Prenatal Diagnosis | 7 | 3.0 |
Carcinogens/*analysis | 2 | 15.0 |
Hydroxylation | 2 | 0.0 |
Glycine | 2 | 2.0 |
Haplotypes/genetics | 7 | 1.0 |
Scandinavia | 2 | 9.0 |
*Chromosome Mapping | 5 | 0.0 |
*Chromosomes, Human, Pair 12 | 6 | 2.0 |
Environmental Exposure/*analysis | 2 | 28.0 |
Pyrenes/analysis | 2 | 66.0 |
Administration, Oral | 2 | 0.0 |
Prospective Studies | 3 | 0.0 |
Gestational Age | 2 | 0.0 |
Ireland/ethnology | 2 | 28.0 |
Scotland/ethnology | 2 | 50.0 |
Sequence Homology, Nucleic Acid | 6 | 0.0 |
Arginine | 2 | 2.0 |
Genes, Recessive | 4 | 0.0 |
Slovakia | 3 | 13.0 |
Turkey | 4 | 2.0 |
Ireland/epidemiology | 3 | 8.0 |
Recombination, Genetic | 3 | 0.0 |
Heterozygote Detection | 7 | 1.0 |
DNA/genetics | 14 | 0.0 |
Fetal Diseases/*diagnosis | 2 | 5.0 |
Questionnaires | 2 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Oligodeoxyribonucleotides | 7 | 0.0 |
DNA/*genetics | 7 | 2.0 |
*Gene Frequency | 3 | 0.0 |
Phenylketonurias/*epidemiology/*genetics | 3 | 100.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
Epidemiology, Molecular | 4 | 4.0 |
Europe/epidemiology | 2 | 2.0 |
*Founder Effect | 2 | 1.0 |
Disease Models, Animal | 3 | 0.0 |
Phenylketonurias/enzymology/genetics/*therapy | 2 | 100.0 |
Gypsies/*genetics | 2 | 18.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
*Evolution, Molecular | 2 | 0.0 |
Genes, Structural/*genetics | 2 | 0.0 |
Hybrid Cells | 5 | 0.0 |
Translocation, Genetic | 2 | 0.0 |
Heat | 2 | 0.0 |
*Meat | 3 | 7.0 |
Oligodeoxyribonucleotides/genetics | 3 | 3.0 |
Phenylalanine Hydroxylase/*deficiency/*genetics | 2 | 100.0 |
Phenylketonurias/*ethnology/*genetics | 2 | 100.0 |
Tyrosine/metabolism | 2 | 0.0 |
Jews/*genetics | 3 | 2.0 |
Mutagenesis | 2 | 0.0 |
Air Pollutants, Occupational/*toxicity | 2 | 18.0 |
Mutagens/*toxicity | 2 | 1.0 |
Hypoxanthine Phosphoribosyltransferase/*genetics | 2 | 4.0 |
Taiwan | 2 | 1.0 |
Liver Neoplasms | 2 | 0.0 |
Oligonucleotide Probes | 11 | 1.0 |
Israel | 3 | 1.0 |
Codon | 2 | 0.0 |
DNA/genetics/isolation & purification | 4 | 1.0 |
Glutamates | 2 | 18.0 |
Glutamic Acid | 3 | 3.0 |
*Transcription, Genetic | 2 | 0.0 |
France/ethnology | 3 | 7.0 |
DNA | 3 | 0.0 |
Phenylalanine Hydroxylase/*genetics/isolation & purification | 2 | 100.0 |
DNA Probes | 7 | 0.0 |
*Linkage (Genetics) | 5 | 0.0 |
Lod Score | 3 | 0.0 |
Nucleic Acid Hybridization | 9 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Tyrosine/*blood | 2 | 5.0 |
*RNA Splicing | 2 | 0.0 |
Crosses, Genetic | 3 | 0.0 |
Genes, Structural | 3 | 0.0 |
Chromosome Deletion | 4 | 0.0 |
Environmental Pollutants/*toxicity | 2 | 5.0 |
Databases, Genetic | 2 | 2.0 |
*Mutagenicity Tests | 2 | 25.0 |
Base Composition | 2 | 0.0 |
Chromosomes, Human, Pair 12 | 4 | 2.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 3 | 1.0 |
Genes | 2 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
DNA/*analysis | 4 | 1.0 |
*Recombination, Genetic | 2 | 0.0 |
*Genes, Structural | 6 | 0.0 |
Demography | 2 | 1.0 |
Gene Amplification | 2 | 0.0 |
Scotland | 2 | 5.0 |
Animals, Newborn | 2 | 0.0 |
*Chromosomes, Human, 6-12 and X | 2 | 1.0 |
Tyrosine 3-Monooxygenase/*genetics | 2 | 1.0 |
Glomerular Filtration Rate | 3 | 2.0 |
Infusions, Parenteral | 2 | 1.0 |
Potassium/urine | 2 | 5.0 |
*Genes, p53 | 2 | 0.0 |
